Anemia of chronic disease is a multifactorial disorder, resulting mainly from inflammationdriven reticuloendothelial iron retention, impaired erythropoiesis, and reduced biological activity of erythropoietin. Erythropoiesis-stimulating agents have been used for anemia of chronic disease treatment, however, with varying response rates and potential adverse effects.
Introduction
Anemia of chronic disease (ACD), also termed anemia of chronic inflammation (ACI), is the most prevalent anemia among hospitalized patients 1, 2 and is primarily found in subjects suffering from diseases with associated chronic immune activation, such as cancer, autoimmune diseases, chronic infection or dialysis dependent renal failure [1] [2] [3] [4] [5] .
A central mechanism, by which chronic immune activation causes anemia, is the retention of iron in the reticuloendothelial system [6] [7] [8] [9] , causing a "functional iron deficiency" and consequently an insufficient iron supply for erythropoiesis 10 . In addition, cytokine mediated effects on erythropoietin functionality and erythrocyte half-life, along with antiproliferative effects of cytokines and radicals on the proliferation and differentiation of erythroid progenitors, further contribute to ACD/ACI pathogenesis 2, [11] [12] [13] .
Hepcidin is a primarily liver derived peptide that orchestrates body iron homeostasis upon binding to cellular iron exporter ferroportin (Fp1) resulting in its internalization and degradation with subsequent reduction of cellular iron egress 14 . As hepcidin is an acute phase protein, its levels are increased in inflammation 7, 15, 16 , which is of pivotal importance for the reticuloendothelial iron retention underlying ACD 3, 6, 7, 9, 10, 17 .
Accordingly, neutralization of hepcidin by specific anti-hepcidin antibodies or spiegelmers 18, 19 as well as pharmacological inhibition of hepcidin formation could either reverse iron retention in the reticuloendothelial system and/or improve anemia in different animal models of inflammatory anemia 20, 21 . In line with this, serum hepcidin has been suggested as a useful marker for patients with ACD 22 .
Overexpression of hepcidin in mice or injection of recombinant hepcidin causes a hypochromic anemia and impaired response to endogenous erythropoietin 10, 23 . Of interest, erythropoietin has been shown to decrease hepcidin expression 24,25 via induction of erythropoiesis 25, 26 . Although erythropoietin treatment decreased liver Hamp (the gene encoding for hepcidin) expression in a mouse model of generalized inflammation 27 , erythropoietin treatment could only partially correct anemia in this model 28 .
As the development of anemia negatively affects the patients' quality of life and impairs basic physiological functions such as cardiovascular performance 29,30 treatment of anemia with erythropoiesis-stimulating agents (ESA; epoetin or darbepoetin alfa) was introduced into clinical practice. This therapy can significantly improve the patients' quality of life 29, 30 but can also result in undesirable side effects, like thrombophilia, stroke and death, as observed in cancer patients or subjects with end stage renal disease [30] [31] [32] . Due to ESA effects on plasma volume, the risk of thrombosis could depend on the required ESA dose 30 . Interestingly, at 4/24 least in dialysis patients, the risk of cardiovascular events is associated with an impaired hematological responsiveness to ESA 33 .
Furthermore, ESA treatment is ineffective in specific patients suffering from ACD/ACI 2, 4 , even if true iron deficiency has been ruled out 34 .
Clinically useful biomarkers which predict the efficacy of ESA treatment are desirable, but
have not been identified thus far. Due to its pivotal role in iron metabolism and the fundamental role of iron in erythropoiesis, hepcidin is a good candidate for such a predictor.
Therefore, we used a well-established arthritis model (PG-APS) in rats, which resembles characteristics of human ACD 7, 35 and studied the biological interaction between hepcidin and ESA treatment in a prospective fashion.
Methods

Animals
Female Lewis rats were kept on a standard rodent diet until they reached an age of 6 to 8
weeks and a body weight of 140 to 160 g. All treatments were performed by intraperitoneal (i.p.) injection.
Chronic inflammation (arthritis) causing ACD was induced as described 21 , using group A streptococcal peptidoglycan-polysaccharide (PG-APS) (Lee Laboratories, Grayson, GA) at a total dose of 15 µg rhamnose/g body weight.
For a short term ESA experiment, untreated ACD rats were compared to ACD rats treated with 500 U of recombinant human erythropoietin (rhEPO, epoetin alfa, EPREX, Janssen Cilag). One group received the rhEPO treatment once (on day 16 after PG-APS injection), the other group thrice on three consecutive days, starting from day 14 after PG-APS injection.
Rats were sacrificed on day 17 after PG-APS injections.
In all following experiments, rats were euthanized 42 days after the induction of arthritis. In these long term experiments, darbepoetin alfa (Aranesp, Amgen, at 10 µg/kg body weight) was used because of its longer half life. Darbepoetin alfa treatments were performed weekly for the indicated periods.
Another treatment modality was the administration of LDN-193189 (LDN, Axon Medchem, Groningen, Netherlands), which was used at a dose of 3 mg/kg body weight and given every second day.
First, rats were treated with darbepoetin alfa for 14, 21, 28 or 35 days before euthanasia. One group of ACD rats received no darbepoetin and control rats were not injected with PG-APS.
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In another experimental setup, ACD rats either received no drug or were treated with darbepoetin alfa alone or in combination with LDN for 21 days before euthanasia. In a further series of independent experiment, ACD animals were injected with LDN alone.
For flow cytometry analysis of bone marrows, we compared healthy controls, untreated ACD rats and ACD rats treated with darbepoetin alfa, LDN or both for 21 days before euthanasia.
For determination of hemoglobin and hepcidin levels over time, small blood samples (300 µL) were taken weekly by tail vein puncture from every animal.
Analysis of rat specimens
For details on complete blood counts (CBC), serum hepcidin 7 and serum iron measurements, Western blotting 7, 36 , RT real-time PCR 37 , macrophage iron export measurements 7 ,
immunofluorescence, bone marrow smears and bone marrow flow cytometry please see the supplemental information.
Statistics
Comparisons between multiple groups in this study were performed by ANOVA with Bonferroni-Holm correction or Dunnett's test for multiple comparisons. A corrected p value below 0.05 was regarded as significant.
Further details on the methods used for this study can be found in the supplement.
Results
ESA therapy inhibits hepatic Hamp mRNA expression in vivo in a rodent model of anemia of chronic disease.
Following our working hypothesis, we first tested if ESAs affect hepcidin expression in a rat model of ACD. Therefore, we injected rhEPO (500 U i.p.) into rats once or on three consecutive days starting two weeks after induction of ACD upon PG-APS injection. As shown in Fig. 1A , both a single as well as three consecutive doses of rhEPO, significantly decreased liver Hamp mRNA expression as compared to untreated animals. Importantly, this was paralleled by reduced serum hepcidin levels in the respective groups (Fig. 1B) .
Long term effect of ESA treatment in ACD
As the short term experiments proved the effectiveness of rhEPO treatment to reduce the hepatic expression of hepcidin in this specific model, we conducted long term experiments to 6/24 study the effects of such interventions on ACD correction. Fig. 2A shows hemoglobin concentrations of ACD animals at day 42 after injection of PG-APS. Depending on the assigned group, animals received ESA treatment for 14, 21, 28 or 35 days, respectively.
Darbepoetin alfa (10 µg/kg) was used for this experiment because of its longer half life. Fig. 2A shows the trend towards higher hemoglobin in ESA treated groups, though this change became significant only for the 28 days ESA treatment group (p<0.01). All ACD groups, either ESA treated or untreated, presented significantly lower hemoglobin levels at the end of the observation period than healthy controls (p<0.001, Fig. 2A ).
We found serum hepcidin to be reduced by ESA treatment (Fig. 2B ), though statistical significance was reached not for all ESA groups. However, serum hepcidin levels in the ESA treated animals were not significantly different from controls, while untreated ACD animals had increased serum hepcidin concentrations (p<0.01, Fig. 2B ). Interestingly, the ESA mediated reduction of hepcidin levels did not translate into significant changes of serum iron concentrations ( Fig. 2C) , and serum iron remained below control levels in all ACD groups (p<0.001, Fig. 2C ).
Differences between the single ESA treatment groups (n=5 to 6 per group) where small and not significant for hemoglobin, serum hepcidin and serum iron. However, the overall effect of ESA for pooled data of ACD rats from all treatment periods showed a significant increase of hemoglobin and serum iron levels (p<0.001, Suppl. Fig. S2 )
When performing Western blot analysis in the spleen after the termination of the experiment (day 42), we found that Fp1 protein levels (Fig. 3A) were lower in ACD as compared to control rats, and this reduction was partially antagonized by ESA treatment in a time dependent fashion (Fig. 3A) . Accordingly, spleen ferritin levels were higher in ACD (Fig. 3A) as compared to control animals, whereas ferritin expression was declining with prolongation of ESA therapy (Fig. 3A ).
These observations in the spleen are paralleled by corresponding changes in the liver (Suppl. To specifically investigate the functional effects of ESA therapy on iron homeostasis on a cellular basis, we studied peritoneal macrophages from healthy controls and from ACD rats, with or without 35 days of darbepoetin alfa treatment, in vitro. We found that 59 Fe release from macrophages derived from ACD rats was significantly lower than from macrophages of control animals (p<0.001, Fig. 3B ), while ESA treatment of ACD rats significantly increased macrophage iron release (p<0.05, Fig. 3B ), which, however, remained lower than in control animals (p<0.001, Fig. 3B ). Importantly, these alterations of macrophage iron export nicely 7/24 correspond to the changes in spleen Fp1 expression observed in ACD animals with and without ESA treatment ( Fig. 3 A- Fe uptake, because uptake is increased in ACD (p<0.001, Fig. 3C ) and not significantly changed by ESA treatment, with a trend towards decrease (Fig. 3C ).
Hepcidin predicts response to ESA treatment
Based on these observations and being aware of the regulatory effects of hepcidin on Fp1 expression 14 , which largely determines circulating iron levels and iron availability for erythropoiesis 21 , and because we observed variations in the responsiveness of rats to ESA treatment ( Fig. 2A, Supplemental Fig. S1 ), we questioned, whether pretreatment serum hepcidin levels may determine the responsiveness of ACD rats to ESA therapy. Mean serum levels of hepcidin in ACD rats at 7, 14 and 21 days after induction of inflammation did not differ significantly (48.4+/-12.5 ng/mL, 62.7+/-18.8 ng/mL, 50.2+/-22.2 ng/mL, mean+/-standard deviation, respectively), indicating that there was no general change over time in pretreatment serum hepcidin levels before initiation of ESA and/or LDN therapy.
We thus performed a correlation analysis between serum hepcidin levels in ACD rats immediately before the start of ESA therapy in the different treatment groups and the consecutive change of hemoglobin concentrations over two weeks, because it took at least two weeks until a significant change in hemoglobin levels upon ESA treatment could be observed (Supplemental Fig. S1 ).
By performing Spearman rank correlation analysis we observed a highly significant negative correlation between pre-treatment serum hepcidin levels and the relative increase of hemoglobin after two weeks of ESA therapy (Fig. 4A , rho=-0.557, p<0.01). In individuals with pre-treatment serum hepcidin levels above 40 ng/ml, blood hemoglobin levels on average declined even with ESA treatment over two weeks of follow up (Fig. 4B ), while lower pre-treatment hepcidin levels (below 40 ng/mg) predicted a better hematological response to ESA therapy (p<0.01, Fig. 4B ). This indicates that high pre-treatment hepcidin levels in rats with ACD are associated with a poor hematological response to ESA therapy. and ESA therapy. Therefore, anemic rats received either darbepoetin alone on a weekly basis or a combination of darbepoetin plus LDN. Importantly, the combined treatment with ESA/LDN resulted in a faster and more sustained increase of hemoglobin levels as compared to treatment with ESA alone (Fig. 5A ).
Hepcidin inhibition improves the therapeutic efficacy of ESA treatment
To see whether the combined effects of ESA and LDN treatments differed from that observed after sole LDN treatment, we analyzed the changes of hemoglobin levels following sole LDN treatment of ACD rats. Interestingly, hemoglobin levels of ACD rats were similar after three weeks of either ESA or LDN treatment ( To further analyze the effects of combined treatment on erythropoiesis, we performed FACS analysis on bone marrows. We studied the percentage of erythroid cells (CD71
(Suppl. Fig. S7B ) and further analyzed maturation stages of erythroid differentiation using anti-rat-erythroid-cells (REC) and anti-CD44 antibodies (Suppl. Fig. S7A ).
In agreement with Richardson et al. 38 we found a dramatic decrease in CD71 The complete blood count data from ESA/LDN experiments can be found in Supplemental   Tables S1 and S2 . Of note, neither treatment resulted in a change in total white blood cell counts (Suppl . Table S2 ) as compared to ACD animals.
Anti-inflammatory effect of ESA/LDN treatment
As erythropoietin has recently been shown to inhibit pro-inflammatory immune effector Erythropoiesis is the main consumer of iron in the human body, and the majority of iron needed for this process originates from macrophages which take up and degrade senescent erythrocytes resulting in re-utilization of iron 6, [42] [43] [44] . The transfer of iron from macrophages to the circulation is largely controlled by the interaction of hepcidin with the iron export protein Fp1. Thus, the high hepcidin levels found in ACD block macrophage iron egress and contribute to an iron restricted erythropoiesis 3, 7, 9, 10, 22 .
Here we demonstrate in a rat model of ACD that higher serum hepcidin levels predict a poorer hematological response to ESA treatment. However, the benefit/risk-ratio of ESA therapy of anemia is still a matter of discussion [30] [31] [32] , which makes the availability of predictive diagnostic markers desirable.
The negative correlation between high circulating hepcidin levels and the response to ESA therapy most likely relates to the fact that higher hepcidin activity is associated with a reduced availability of iron for erythropoiesis. Our observation is in agreement with the observation by Prentice and co-workers who found that hepcidin is the major predictor of iron incorporation into red cells in anemic children in Africa 45 . As hepcidin is regulated by various stimuli such as hypoxia, anemia, iron or inflammation 3, 15, 17 it is of importance to consider which regulatory mechanism underlies the poor predictive effect of high hepcidin levels for the response to ESA therapy. We could demonstrate that ESA treatment reduced serum hepcidin and liver Hamp mRNA expression in rats with ACD. In accordance with the changes in hepcidin levels, ESA treatment of ACD rats reduced iron storage in the spleen as evidenced by reduced ferritin levels and increased iron mobilization from macrophages of ACD animals.
However, this ESA driven iron mobilization was insufficient, as demonstrated by a nonsignificant increase of serum iron levels and unaffected MCV and MCH which also translated to minimum improvement of anemia. Importantly, high hepcidin levels were associated with a reduced therapeutic efficacy of ESA, which prompted us to study the combined effects of In summary, we provide evidence that predicting the response to ESA therapy by measuring pre-treatment hepcidin levels and upon applying a combined treatment of ESA and hepcidin antagonizing agents can improve the therapeutic efficacy of ESA therapy. In patient treatment secondary benefits could be a reduction of dosages, costs and most importantly undesired or serious adverse effects of ESA treatment. Once anti-hepcidin strategies become clinically available this strategy of combination therapy has to be studied in a randomized prospective 13/24 fashion also keeping in mind to evaluate the effect of anemia correction on the course of the diseases underlying ACD.
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19/24 Endpoint data are depicted, as lower quartile, median and upper quartile (boxes) and minimum/maximum ranges (whiskers).
Statistical significances of differences were calculated using ANOVA and Bonferroni-Holm correction for multiple comparisons. All groups were compared to each other. Only One representative out of at least three Western blots of spleen Fp1 and ferritin (A) are shown.
Beta actin was used as a loading control. n=10 for controls, n=6 for ACD and n=5 to 6 for each single ACD-ESA group, see Fig.2 .
In another experiment (B-C), peritoneal macrophages were taken from control rats, ACD rats ACD was induced by injection of PG-APS in rats on day 0. On day 42 all animals were euthanized. Groups of ACD rats were treated with darbepoetin alfa (ESA) for either 35, 28, 21 or 14 days before euthanasia. Data is from the same ACD animals as in Fig. 2 and Fig. 3A .
Serum hepcidin concentrations prior to onset of ESA treatment of ACD animals are plotted against the relative change of hemoglobin over the first two weeks of ESA treatment (hemoglobin after two weeks of ESA treatment minus hemoglobin concentrations before ESA treatment).
(A) The linear regression is shown. Spearman's rank correlation reveals a highly significant negative correlation between these two parameters (rho=-0.557, p<0.01).
(B) Animals are divided into two groups according to low (<40 ng/ml) and high (>40 ng/ml) pre-treatment serum hepcidin levels. Data are depicted as lower quartile, median and upper quartile (boxes) and minimum/maximum ranges (whiskers). The statistical significance of the difference in hemoglobin change between the two groups was calculated by Student's t-test (p<0.01).
22/24 Bone marrow cellularity and the ratio of granulopoiesis to erythropoiesis are shown in (H, I).
The SMAD1/5/8 complex was detected by Western blotting in liver nuclear extracts (J).
TATA binding protein (1TBP18 antibody) was detected in the respective samples as a nuclear loading control. One representative out of three blots is shown.
Statistical significance of differences between groups was calculated using ANOVA with Bonferroni-Holm correction for multiple testing.
23/24 Statistical significance of differences between groups was calculated using ANOVA with Bonferroni-Holm correction for multiple testing. Data were logarithmized to reach homogeneity of variance.
Supplemental Methods
Animals
Female Lewis rats (Charles River Laboratories, Sulzfeld, Germany) were kept on a standard rodent diet (180 mg Fe/kg, C1000 from Altromin, Lage, Germany) until they reached an age ESA doses were freshly adjusted to 500 µL with 0.85% saline per rat. LDN-193189 was freshly dissolved in 500 µL 0.85% saline per rat.
Small weekly blood samples (300 µL) from tail vein punctures were used for complete blood counts (CBC) analysis on a Vet-ABC animal blood counter (Scil Animal Care Company, Viernheim, Germany) and serum hepcidin measurements.
At the end of the experiments, rats were anesthetized and blood was taken by retrobulbar puncture. CBC analysis was performed and serum was prepared for serum hepcidin measurement.
Serum iron was measured using the QuantiChrom iron assay kit (BioAssay Systems, Hayward, CA) according to the manufacturer's instructions.
Serum hepcidin determination
Determination of hepcidin in rat serum was performed by mass spectrometry as detailed elsewhere 1 .
RNA preparation from tissue, reverse transcription, and TaqMan real-time PCR
Total RNA preparation from nitrogen-frozen rat tissue, reverse transcription of 4 µg RNA, and TaqMan or EvaGreen real-time polymerase chain reaction (PCR) were performed as previously described 
Western blotting
Cytoplasmic protein was extracted from freshly isolated tissue and Western blotting was performed as previously described 3 . Anti-ferritin antibody (2 μg/mL, Dako, Austria), anti-ratferroportin-antibody 1 or anti-actin (2 μg/mL, Sigma, Germany) were used as described previously 3 .
Nuclear extracts were prepared from freshly isolated tissue using a commercially available kit (NE-PER, Thermo scientific, Rockford, USA). Western blotting of nuclear extracts was performed as described for cytoplasmic extracts. Phospho-Smad1/Smad5/Smad8-antibody (0.1 μg/mL, Cell Signaling Technology, Inc., Danvers, USA) and TATA binding protein (1TBP18, final concentration 0.1μg/mL from Abcam, Cambridge, UK) were used as described previously 3 .
Immunofluorescence (IF)
Formalin fixed and paraffin-wax embedded rat spleen and duodenum samples were cut at 3 µm thickness.
After deparaffinization in xylenes and rehydration in graded ethanol, a proteinase based antigen retrieval was performed. Slides were incubated in 60 µg/mL proteinase K (Roche, After three washes in PBS, donkey anti rabbit Alexa 555 (Invitrogen, Germany) 1:800 in PBS/1% BSA was applied as secondary antibody for 30' at RT.
After three more washes, slides were coversliped with Roti-Mount FluorCare DAPI (Carl Roth, Germany).
Micrographs were taken with constant exposure conditions for each organ on a Zeiss Axioskop 2 microscope (Carl Zeiss Microscopy, Jena, Germany) equipped with a ProgRes
C14plus camera (Jenoptik, Jena, Germany) using the ProgRes CapturePro 2.8.8 software for capturing.
Quantification of macrophage iron transport
For macrophage iron uptake and release studies, resident peritoneal macrophages were harvested from control and anemic rats by peritoneal lavage immediately after the Fe free medium for 2 hours. The supernatants were used for gamma counting.
Bone marrow smears
For preparation of bone marrow smears both ends of the harvested rat femur were cut off. The bone was then placed in a specially prepared 4 1.5 mL tube and centrifuged (2 min., 100 x g).
Harvested bone marrow cells were immediately diluted in 100 µL 1xPBS with 1 mM EDTA, three smears were prepared from the total volume and stained using May-Grünwald-Giemsa (panoptic) technique.
Semiquantitative myelograms and morphologic description were done in a blinded fashion by a hematologist experienced in the analysis of rodent bone marrow smears. Representative fields from three smears per animal were evaluated for cellularity and expressed as averaged percentage of the visual fields.
In each representative visual field cellularity was estimated and 100 cells were counted with respect to G:E ratio and maturation profiles (myelograms) in all hematopoietic lines. For evaluation a Zeiss Axioscope 40 microscope with 5x, 10x, 40x and 100x lenses was used.
Representative fields were photo documented on a pixel link system.
Flow cytometry
Data were collected on a FACSVerse instrument (BD) and analyzed using FlowJo software (TreeStar Inc). Using FACSVerse allows for cell counting while performing FACS analysis.
Fluorochrome-conjugated antibodies were purchased from BD: APC-anti-rat erythroid cells 
Statistics
Statistical analysis was carried out using SPSS software package version 17.1 (SPSS Inc., Chicago, IL).
